专利检索_...来源于阿黑皮素原脑啡肽原或强啡肽原专利检索_...来源于阿黑皮素原脑啡肽原或强啡肽原专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
81		JP54678798	1998-04-26	JP2001524968A	2001-12-04

82		JP2000503850	1998-07-23	JP2001515841A	2001-09-25

83		JP51213697	1996-09-12	JPH11512438A	1999-10-26

84		JP50529895	1995-07-18	JPH10507740A	1998-07-28

85		JP53005895	1995-05-22	JPH10500423A	1998-01-13
PCT No. PCT/EP95/01931 Sec. 371 Date Nov. 21, 1996 Sec. 102(e) Date Nov. 21, 1996 PCT Filed May 22, 1995 PCT Pub. No. WO95/31985 PCT Pub. Date Nov. 30, 1995The combined use of opiate antagonists and of calcium salts for the preparation of medicaments for the treatment of endorphin-mediated pathologies is described.
86	BIOLOGICALLY ACTIVE PEPTIDE COMPOSITION FOR NASAL ABSORPTION	JP15477396	1996-05-28	JPH09255586A	1997-09-30	YANAGAWA AKIRA
PROBLEM TO BE SOLVED: To obtain a peptide composition excellent in absorption on nasal administration and free from irritation by using a material effective on repairing and protecting mucosal tissue as a specific carrier for a nasal absorption composition and homogeneously dispersing and allowing to absorb and bind a biologically active peptide on the carrier. SOLUTION: (A) An effective dose of a biologically active peptide and (B) a material effective on repairing and protecting mucosal tissue (preferably, a material effective on repairing and protecting the gastric mucosa) are together homogeneously dispersed. As the component A, a peptide hormone (preferably, calcitonin or insulin), a biologically active protein or an enzymatic protein is preferably cited. Further, as the component B, gefarnate, aceglutamide aluminum, sucralfate, L-glutamine, etc., is preferably cited.
87	NOVEL PLASMID AND NOVEL MICROORGANISM TRANSFORMED BY SAID PLASMID	JP16828885	1985-07-30	JPS6229982A	1987-02-07	HORIKOSHI KOKI; KUDO TOSHIAKI; KOBAYASHI TETSUO; KATO CHIAKI
NEW MATERIAL:A plasmid (pEAP7DELTAP plasmid shown in Fig. I) having a DNA region capable of giving extracellular secretion promoting action of a useful physiologically active substance, e.g. xylanase, to a host cell and a promoter DNA region capable of regulating the expression of the DNA region and microorganism, e.g. Escherichia coli HB101, transformed by the plasmid. USE:Production of enzymes, hormones, immunologically active substances, etc. PREPARATION:A chromosome DNA of Bacillus sp. No.170 is treated with a restriction enzyme to give a plasmid pEAP1 shown in Fig. 2. Natural deciduation of 4kb therefrom is carried out to afford a pEAP3 plasmid, which is then treated with a restriction enzyme to give the above-mentioned pEAP7DELTAP plasmid. The resultant plasmid is then added to a cultivated cell suspension of Escherichia coli HB101 in LB culture medium, e.g. trypton, reacted while cooling with ice and incorporated in the cell to transform the cell.
88	ANTINEOPLASTIC DRUG	JP17525582	1982-10-05	JPS58126811A	1983-07-28	NIKORASU PII PUROTONIKOFU

89	PEPTIDE OPIOIDE	JP2070781	1981-02-13	JPS57134451A	1982-08-19	MATSUO TOSHIYUKI; SAGAWA KENJI; MINAMINO NAOTO; MIZUNO KENSAKU; HAYASHI YUUJIROU; SAKAKIBARA SHIYUNPEI; KAYANO NAOYOSHI
NEW MATERIAL:Peptide opioide of formulaI[Tyr is tyrosine; Gly is glycine; Phe is phenylalanine; Leu is leucine residue; R is formula II (Arg is arginine; LyS is lysine; Pro is proline), formula III (Ile is isoleucine) which is connected to the terminal of Leu]. EXAMPLE:Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro. USE:Morphine-like analgesic. PREPARATION:Pig hypothalamus, after defatted, is extracted with acetic acid to collect the low-molecular fraction. Then, G-fraction is collected from the basic fraction eluted with ammonia as a fraction eluting before alpha-neo-endorphin and subjected to gel filtration. The eluate is subjected to high-speed liquid chromatography to effect purification and beta-neo-endorphin and pH-8P are obtained from the selected two peaks where R is formula II of the formulaIin the former and R is formula III in the latter.
90	Compounds and methods for treating pain	US15774451	2016-11-09	US10899796B2	2021-01-26	Alan S. Kopin; Krishna Kumar; Jamie Raudensky Doyle
The present disclosure relates to, among other things, compounds and methods for treating neuropathic pain, ocular pain, ocular inflammation, and/or dry eye and methods of detecting mutations in specific G-protein coupled receptors, such as missense mutations, and determining the extent to which these mutations alter the pharmacological response of the G-protein coupled receptor.
91	Cancer therapy	US14351766	2014-04-11	US10195219B2	2019-02-05	Rebecca Lambert Bent
The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.
92	Activated polyoxazolines and conjugates and compositions comprising the same	US15453686	2017-03-08	US10086084B2	2018-10-02	J Milton Harris; Michael David Bentley; Kunsang Yoon; Zhihao Fang; Francesco Maria Veronese; Tacey Viegas
The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.
93	Use of a peptide and an analgesic pharmaceutical agent	US12449944	2008-03-07	US09486493B2	2016-11-08	Andrzej W. Lipkowski; Daniel Carr; Aleksandra Misicka-Kesik; Piotr Kosson; Anna Klinowiecka
Inflammation caused by disease states such as rheumatism, gout, neurodegeneration and tumours result in the increased effectiveness of the opioid peptide biphalin or its analogues, due likely to the increased permeability of the “blood-brain barrier”, due to which it becomes possible to use the opioid peptide to produce a new analgesic for use during inflammation caused by rheumatism, gout, neurodegeneration, post-surgical or post-accidental trauma or tumours.
94	Delta opioid receptor agonist compounds	US14503758	2014-10-01	US09296707B2	2016-03-29	Kwen-Jen Chang; Klim King; Kestutis P. Biciunas; Robert W. McNutt; William Pendergast; Shyi-Tai Jan
Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.
95	COMBINATION OF A MC1R RECEPTOR AGONIST AND UVB FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS	US14385416	2013-03-15	US20150045719A1	2015-02-12	Carole Chomat; Philippe Martel; Johannes Voegel
A system comprising a combination of at least one MC1R receptor agonist and a source of NB-UVB, wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation.
96	Delta opioid receptor agonist compounds	US14042893	2013-10-01	US08865721B2	2014-10-21	Kwen-Jen Chang; Klim King; Kestutis P. Biciunas; Robert W. McNutt; William Pendergast; Shyi-Tan Jan
Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.
97	SUSTAINED-RELEASE COMPOSITION CONTAINING PEPTIDES AS ACTIVE INGREDIENT	US14126365	2012-06-13	US20140127303A1	2014-05-08	Joël Richard; Faïza Laredj; Maire-Madeleine Baronnet; Didier Nourrisson; Jeremiah Harnett; Béatrice Hacher; Nathalie Mondoly; Laurent Bertocchi
The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.
98	FORMULATION	US13836547	2013-03-15	US20130344102A1	2013-12-26	David John Shotton; Syed Ebadat Haq; Deirdre Patricia McIntosh
The present invention relates to a CRH formulation having improved stability/efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.
99	Lytic peptide prodrugs	US09938623	2001-08-27	US07456146B2	2008-11-25	Xianxhang Yu; Thomas E. Wagner
A cytotoxin can be rendered non-toxic by charge neutralizing the amino acids salient to pore assembly and/or sterically inhibiting formation of the peptide's active conformation. In the presence of specific proteases, the inactive peptide or procytotoxin can be activated to assemble into its lytic conformation and selectively destroy a target cell.
100	Therapy procedure for drug delivery for trigeminal pain	US11511569	2006-08-28	US20070093420A1	2007-04-26	David Yeomans; William Frey; Daniel Jacobs
The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.

1 2 3 4 5 6 7 8 9 10

IPRDB

热门服务

关于我们

友情链接

联系方式